Biogen Inc. (0R1B.L)
USD 122.4
(-0.53%)
USD 122.4
(-0.53%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 5.2 Billion USD | 9.57% |
| 2022 | 4.99 Billion USD | -17.66% |
| 2021 | 6.06 Billion USD | -15.7% |
| 2020 | 7.19 Billion USD | 33.53% |
| 2019 | 5.38 Billion USD | -4.42% |
| 2018 | 5.63 Billion USD | 10.16% |
| 2017 | 5.11 Billion USD | 18.51% |
| 2016 | 4.31 Billion USD | -4.25% |
| 2015 | 4.5 Billion USD | -2.32% |
| 2014 | 4.61 Billion USD | 28.77% |
| 2013 | 3.58 Billion USD | 14.43% |
| 2012 | 3.13 Billion USD | 10.37% |
| 2011 | 2.83 Billion USD | 3.31% |
| 2010 | 2.74 Billion USD | 1.75% |
| 2009 | 2.69 Billion USD | 9.89% |
| 2008 | 2.45 Billion USD | 24.54% |
| 2007 | 1.97 Billion USD | -0.93% |
| 2006 | 1.99 Billion USD | 17.5% |
| 2005 | 1.69 Billion USD | 5.01% |
| 2004 | 1.61 Billion USD | 27.66% |
| 2003 | 1.26 Billion USD | 82.79% |
| 2002 | 691.56 Million USD | 26.51% |
| 2001 | 546.65 Million USD | 15.6% |
| 2000 | 472.89 Million USD | 28.79% |
| 1999 | 367.17 Million USD | 25.56% |
| 1998 | 292.43 Million USD | 24.5% |
| 1997 | 234.88 Million USD | 13.07% |
| 1996 | 207.73 Million USD | 55.33% |
| 1995 | 133.74 Million USD | -9.82% |
| 1994 | 148.3 Million USD | 35.81% |
| 1993 | 109.2 Million USD | 17.55% |
| 1992 | 92.9 Million USD | 378.87% |
| 1991 | 19.4 Million USD | 39.57% |
| 1990 | 13.9 Million USD | 13.01% |
| 1989 | 12.3 Million USD | 7.89% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 965.1 Million USD | -26.35% |
| 2024 Q2 | 995.8 Million USD | 3.18% |
| 2024 Q3 | 1.37 Billion USD | 38.19% |
| 2023 Q4 | 1.31 Billion USD | -19.9% |
| 2023 Q3 | 1.63 Billion USD | 31.71% |
| 2023 Q1 | 1.28 Billion USD | -11.19% |
| 2023 FY | 5.47 Billion USD | 9.57% |
| 2023 Q2 | 1.24 Billion USD | -3.19% |
| 2022 Q2 | 1.19 Billion USD | 5.45% |
| 2022 FY | 4.99 Billion USD | -17.66% |
| 2022 Q4 | 1.44 Billion USD | 18.97% |
| 2022 Q3 | 1.21 Billion USD | 1.35% |
| 2022 Q1 | 1.13 Billion USD | -23.65% |
| 2021 Q2 | 1.81 Billion USD | 41.97% |
| 2021 FY | 6.06 Billion USD | -15.7% |
| 2021 Q3 | 1.48 Billion USD | -17.81% |
| 2021 Q4 | 1.48 Billion USD | -0.03% |
| 2021 Q1 | 1.27 Billion USD | -55.2% |
| 2020 FY | 7.19 Billion USD | 33.53% |
| 2020 Q3 | 1.86 Billion USD | 45.38% |
| 2020 Q1 | 1.18 Billion USD | -19.84% |
| 2020 Q2 | 1.28 Billion USD | 8.09% |
| 2020 Q4 | 2.84 Billion USD | 52.33% |
| 2019 Q3 | 1.43 Billion USD | 19.32% |
| 2019 Q2 | 1.2 Billion USD | -4.11% |
| 2019 FY | 5.38 Billion USD | -4.42% |
| 2019 Q1 | 1.25 Billion USD | -16.85% |
| 2019 Q4 | 1.48 Billion USD | 3.13% |
| 2018 FY | 5.63 Billion USD | 10.16% |
| 2018 Q3 | 1.33 Billion USD | -18.79% |
| 2018 Q2 | 1.64 Billion USD | 43.64% |
| 2018 Q1 | 1.14 Billion USD | -13.93% |
| 2018 Q4 | 1.51 Billion USD | 13.3% |
| 2017 Q3 | 1.02 Billion USD | -25.26% |
| 2017 Q1 | 1.39 Billion USD | 21.59% |
| 2017 Q4 | 1.32 Billion USD | 29.81% |
| 2017 Q2 | 1.37 Billion USD | -1.54% |
| 2017 FY | 5.11 Billion USD | 18.51% |
| 2016 Q4 | 1.14 Billion USD | 4.43% |
| 2016 Q1 | 1.02 Billion USD | -16.2% |
| 2016 Q2 | 1.05 Billion USD | 2.87% |
| 2016 Q3 | 1.09 Billion USD | 4.11% |
| 2016 FY | 4.31 Billion USD | -4.25% |
| 2015 FY | 4.5 Billion USD | -2.32% |
| 2015 Q4 | 1.22 Billion USD | 11.46% |
| 2015 Q3 | 1.09 Billion USD | 1.97% |
| 2015 Q2 | 1.07 Billion USD | -3.78% |
| 2015 Q1 | 1.11 Billion USD | -5.43% |
| 2014 Q1 | 1.18 Billion USD | 12.26% |
| 2014 Q3 | 1.11 Billion USD | -2.69% |
| 2014 FY | 4.61 Billion USD | 28.77% |
| 2014 Q4 | 1.18 Billion USD | 6.39% |
| 2014 Q2 | 1.14 Billion USD | -3.64% |
| 2013 Q3 | 915.59 Million USD | 8.91% |
| 2013 FY | 3.58 Billion USD | 14.43% |
| 2013 Q1 | 773.59 Million USD | -8.99% |
| 2013 Q2 | 840.7 Million USD | 8.67% |
| 2013 Q4 | 1.05 Billion USD | 15.17% |
| 2012 Q1 | 789.16 Million USD | 1.52% |
| 2012 Q3 | 732.4 Million USD | -3.9% |
| 2012 Q4 | 850.04 Million USD | 16.06% |
| 2012 Q2 | 762.11 Million USD | -3.43% |
| 2012 FY | 3.13 Billion USD | 10.37% |
| 2011 FY | 2.83 Billion USD | 3.31% |
| 2011 Q4 | 777.33 Million USD | 11.67% |
| 2011 Q3 | 696.11 Million USD | 0.14% |
| 2011 Q2 | 695.13 Million USD | 4.35% |
| 2011 Q1 | 666.15 Million USD | 50.22% |
| 2010 Q1 | 708.11 Million USD | 9.96% |
| 2010 FY | 2.74 Billion USD | 1.75% |
| 2010 Q4 | 443.45 Million USD | -49.93% |
| 2010 Q3 | 885.73 Million USD | 24.78% |
| 2010 Q2 | 709.83 Million USD | 0.24% |
| 2009 Q4 | 643.97 Million USD | 0.17% |
| 2009 Q3 | 642.85 Million USD | -17.55% |
| 2009 FY | 2.69 Billion USD | 9.89% |
| 2009 Q1 | 633.32 Million USD | -14.55% |
| 2009 Q2 | 779.65 Million USD | 23.1% |
| 2008 FY | 2.45 Billion USD | 24.54% |
| 2008 Q1 | 548.84 Million USD | 8.11% |
| 2008 Q2 | 570.81 Million USD | 4.0% |
| 2008 Q3 | 596.08 Million USD | 4.43% |
| 2008 Q4 | 741.16 Million USD | 24.34% |
| 2007 FY | 1.97 Billion USD | -0.93% |
| 2007 Q2 | 482.77 Million USD | 9.86% |
| 2007 Q3 | 554.29 Million USD | 14.81% |
| 2007 Q4 | 507.68 Million USD | -8.41% |
| 2007 Q1 | 439.43 Million USD | -43.12% |
| 2006 Q3 | 439.19 Million USD | 7.51% |
| 2006 Q4 | 772.57 Million USD | 75.91% |
| 2006 Q2 | 408.53 Million USD | 10.12% |
| 2006 Q1 | 370.99 Million USD | -9.73% |
| 2006 FY | 1.99 Billion USD | 17.5% |
| 2005 Q4 | 410.99 Million USD | -11.51% |
| 2005 FY | 1.69 Billion USD | 5.01% |
| 2005 Q2 | 412.67 Million USD | -0.06% |
| 2005 Q1 | 412.91 Million USD | -7.52% |
| 2005 Q3 | 464.43 Million USD | 12.54% |
| 2004 Q3 | 407.98 Million USD | 5.01% |
| 2004 Q4 | 446.49 Million USD | 9.44% |
| 2004 FY | 1.61 Billion USD | 27.66% |
| 2004 Q1 | 370.84 Million USD | -43.94% |
| 2004 Q2 | 388.5 Million USD | 4.76% |
| 2003 Q1 | 180.52 Million USD | 1.65% |
| 2003 Q3 | 213.81 Million USD | 2.68% |
| 2003 Q4 | 661.54 Million USD | 209.4% |
| 2003 Q2 | 208.23 Million USD | 15.34% |
| 2003 FY | 1.26 Billion USD | 82.79% |
| 2002 Q3 | 177.19 Million USD | -2.06% |
| 2002 Q4 | 177.59 Million USD | 0.23% |
| 2002 Q2 | 180.91 Million USD | 16.08% |
| 2002 Q1 | 155.85 Million USD | 2.68% |
| 2002 FY | 691.56 Million USD | 26.51% |
| 2001 Q2 | 134.38 Million USD | 10.76% |
| 2001 Q3 | 139.14 Million USD | 3.55% |
| 2001 Q4 | 151.79 Million USD | 9.09% |
| 2001 FY | 546.65 Million USD | 15.6% |
| 2001 Q1 | 121.33 Million USD | 1.24% |
| 2000 Q1 | 104.18 Million USD | 36.41% |
| 2000 Q3 | 136.24 Million USD | 20.97% |
| 2000 Q2 | 112.62 Million USD | 8.09% |
| 2000 Q4 | 119.84 Million USD | -12.04% |
| 2000 FY | 472.89 Million USD | 28.79% |
| 1999 Q1 | 91.5 Million USD | 46.31% |
| 1999 Q3 | 102.6 Million USD | 5.99% |
| 1999 Q4 | 76.37 Million USD | -25.56% |
| 1999 FY | 367.17 Million USD | 25.56% |
| 1999 Q2 | 96.8 Million USD | 5.79% |
| 1998 Q2 | 76.6 Million USD | 11.5% |
| 1998 Q4 | 62.53 Million USD | -25.46% |
| 1998 FY | 292.43 Million USD | 24.5% |
| 1998 Q1 | 68.7 Million USD | 38.82% |
| 1998 Q3 | 83.9 Million USD | 9.53% |
| 1997 Q3 | 64.1 Million USD | 11.48% |
| 1997 FY | 234.88 Million USD | 13.07% |
| 1997 Q1 | 63.5 Million USD | 8.11% |
| 1997 Q2 | 57.5 Million USD | -9.45% |
| 1997 Q4 | 49.48 Million USD | -22.8% |
| 1996 FY | 207.73 Million USD | 55.33% |
| 1996 Q4 | 58.73 Million USD | 9.38% |
| 1996 Q3 | 53.7 Million USD | 0.37% |
| 1996 Q2 | 53.5 Million USD | 27.99% |
| 1996 Q1 | 41.8 Million USD | 45.94% |
| 1995 Q3 | 36.4 Million USD | 0.83% |
| 1995 Q4 | 28.64 Million USD | -21.31% |
| 1995 FY | 133.74 Million USD | -9.82% |
| 1995 Q2 | 36.1 Million USD | 10.4% |
| 1995 Q1 | 32.7 Million USD | 37.96% |
| 1994 FY | 148.3 Million USD | 35.81% |
| 1994 Q1 | 31.1 Million USD | -22.83% |
| 1994 Q2 | 35.6 Million USD | 14.47% |
| 1994 Q3 | 57.9 Million USD | 62.64% |
| 1994 Q4 | 23.7 Million USD | -59.06% |
| 1993 FY | 109.2 Million USD | 17.55% |
| 1993 Q2 | 23.7 Million USD | 7.24% |
| 1993 Q1 | 22.1 Million USD | -68.96% |
| 1993 Q4 | 40.3 Million USD | 64.49% |
| 1993 Q3 | 24.5 Million USD | 3.38% |
| 1992 FY | 92.9 Million USD | 378.87% |
| 1992 Q3 | 11.2 Million USD | 103.64% |
| 1992 Q4 | 71.2 Million USD | 535.71% |
| 1992 Q2 | 5.5 Million USD | 3.77% |
| 1992 Q1 | 5.3 Million USD | 3.92% |
| 1991 FY | 19.4 Million USD | 39.57% |
| 1991 Q2 | 5 Million USD | 11.11% |
| 1991 Q4 | 5.1 Million USD | 8.51% |
| 1991 Q3 | 4.7 Million USD | -6.0% |
| 1991 Q1 | 4.5 Million USD | 25.0% |
| 1990 Q1 | 3.6 Million USD | 2.86% |
| 1990 Q4 | 3.6 Million USD | 2.86% |
| 1990 Q3 | 3.5 Million USD | 2.94% |
| 1990 Q2 | 3.4 Million USD | -5.56% |
| 1990 FY | 13.9 Million USD | 13.01% |
| 1989 Q2 | - USD | 0.0% |
| 1989 FY | 12.3 Million USD | 7.89% |
| 1989 Q1 | - USD | 100.0% |
| 1989 Q3 | 3 Million USD | 0.0% |
| 1989 Q4 | 3.5 Million USD | 16.67% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Editas Medicine, Inc. | 247.3 Million USD | -2004.657% |
| Dynavax Technologies Corporation | 219.14 Million USD | -2275.094% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -3553.51% |
| Walgreens Boots Alliance, Inc. | 40.6 Billion USD | 87.18% |
| Supernus Pharmaceuticals, Inc. | 529.01 Million USD | -883.893% |
| Perrigo Company plc | 1.52 Billion USD | -240.523% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -1787.933% |
| Illumina, Inc. | 3.81 Billion USD | -36.504% |
| Thermo Fisher Scientific Inc. | 10.25 Billion USD | 49.24% |
| Nektar Therapeutics | 190.9 Million USD | -2626.463% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -1054.098% |
| IQVIA Holdings Inc. | 2.05 Billion USD | -153.527% |
| Heron Therapeutics, Inc. | 120.65 Million USD | -4213.799% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -11552.674% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | -198.057% |
| Waters Corporation | 943.51 Million USD | -451.649% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -2176.063% |
| Adicet Bio, Inc. | 152.03 Million USD | -3323.42% |
| Evolus, Inc. | 189.75 Million USD | -2642.9% |
| bluebird bio, Inc. | 240.23 Million USD | -2066.614% |
| Aclaris Therapeutics, Inc. | 12.14 Million USD | -42770.439% |
| Esperion Therapeutics, Inc. | 271.89 Million USD | -1814.291% |
| FibroGen, Inc. | 398.11 Million USD | -1207.393% |
| Agilent Technologies, Inc. | 2.11 Billion USD | -146.095% |
| Homology Medicines, Inc. | 9.87 Million USD | -52607.848% |
| Geron Corporation | 70.44 Million USD | -7289.021% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | -189.151% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -37319.37% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -1117.091% |
| Myriad Genetics, Inc. | 600.1 Million USD | -767.339% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | -84.879% |
| OPKO Health, Inc. | 574.68 Million USD | -805.695% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -5062.209% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -843.659% |
| Zoetis Inc. | 2.76 Billion USD | -88.242% |
| Abeona Therapeutics Inc. | 48.5 Million USD | -10631.31% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | -377.781% |
| Exelixis, Inc. | 1.58 Billion USD | -228.017% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | -9.003% |
| uniQure N.V. | 285.08 Million USD | -1725.73% |
| Kala Pharmaceuticals, Inc. | 39.15 Million USD | -13193.745% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -9235.139% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -992.64% |
| Verastem, Inc. | 92.08 Million USD | -5552.339% |
| Imunon, Inc. | 21.03 Million USD | -24649.375% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -567.648% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | -282.483% |
| Neurocrine Biosciences, Inc. | 1.59 Billion USD | -226.019% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -1312.027% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -1638.92% |
| TG Therapeutics, Inc. | 198.47 Million USD | -2522.446% |
| Blueprint Medicines Corporation | 722.86 Million USD | -620.042% |
| Insmed Incorporated | 949.26 Million USD | -448.311% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -1173.196% |
| Incyte Corporation | 1.19 Billion USD | -337.205% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -398.554% |